NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis $0.94 +0.03 (+2.76%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$0.95 +0.01 (+1.57%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Allarity Therapeutics Stock (NASDAQ:ALLR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allarity Therapeutics alerts:Sign Up Key Stats Today's Range$0.89▼$0.9650-Day Range$0.83▼$1.4352-Week Range$0.77▼$1.84Volume97,140 shsAverage Volume138,982 shsMarket Capitalization$14.88 millionP/E RatioN/ADividend YieldN/APrice Target$10.25Consensus RatingHold Company Overview Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology. The company has also evaluated other targeted cancer therapies and drug combinations through its precision-medicine platform. Allarity does not have commercially approved products and remains focused on clinical development and regulatory activities. The company originated in Denmark under the name Oncology Venture and adopted the Allarity Therapeutics name in 2021. Its operations and research activities have been associated with Denmark and the United States, while its investigational programs have been intended for international clinical development. Information about current leadership and active development programs may change as the company’s clinical and corporate plans evolve.AI Generated. May Contain Errors. Read More Allarity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreALLR MarketRank™: 1.823429096155 of 5 starsAllarity Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 723rd out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAllarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAllarity Therapeutics has a consensus price target of $10.25, representing about 995.9% upside from its current price of $0.94.Amount of Analyst CoverageAllarity Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Allarity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.80) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allarity Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allarity Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllarity Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Allarity Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 1.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 37.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.89 News SentimentAllarity Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.16% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by Institutions11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLR Stock News HeadlinesAllarity Therapeutics (ALLR) Expected to Post Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comAllarity Therapeutics Signs First Revenue-Generating CLIA Services Deal; Stock DownOctober 31, 2026 | rttnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 12 at 1:00 AM | Weiss Ratings (Ad)Allarity Therapeutics Ends Stock Purchase Agreement, Shifts FinancingOctober 30, 2026 | tipranks.comAllarity Therapeutics Announces First Commercial CLIA Laboratory Services AgreementOctober 30, 2026 | quiverquant.comQAllarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring RevenueOctober 30, 2026 | globenewswire.comHere's why Allarity Therapeutics, Inc. (ALLR) is a great buy the bottom stock nowOctober 10, 2026 | msn.comAllarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical DevelopmentSeptember 30, 2026 | finance.yahoo.comSee More Headlines ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed this year? Allarity Therapeutics' stock was trading at $1.08 at the beginning of the year. Since then, ALLR stock has decreased by 13.4% and is now trading at $0.9353. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. When did Allarity Therapeutics' stock split? Allarity Therapeutics shares reverse split before market open on Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How will Allarity Therapeutics' stock buyback program work? Allarity Therapeutics' Board of Directors approved a stock buyback plan on Monday, March 3rd 2025, which permits the company to repurchase $5 million in shares, according to EventVestor. This means that the company could repurchase up to 128.1% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board believes its shares are undervalued. Who are Allarity Therapeutics' major shareholders? Allarity Therapeutics' top institutional investors include State Street Corp (0.97%). How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allarity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include Advanced Micro Devices (AMD), Ford Motor (F), NVIDIA (NVDA), Invesco QQQ (QQQ), Rocket One Inc. Common Stock (RKTO), Tenax Therapeutics (TENX) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/14/2026Today11/12/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, ALLR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALLR CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees8Year Founded2004Price Target and Rating Average Price Target for Allarity Therapeutics$10.25 High Price Target$10.25 Low Price Target$10.25 Potential Upside/Downside+995.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-152.77% Return on Assets-46.50% Debt Debt-to-Equity RatioN/A Current Ratio1.11 Quick Ratio1.11 Sales & Book Value Annual Sales$345 thousand Price / Sales43.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.53Miscellaneous Outstanding Shares15,911,000Free Float15,886,000Market Cap$14.88 million OptionableNot Optionable Beta0.57 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ALLR) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts